Member Info for danrh

Half-yearly result don’t get much better than this!

Half-year highlights
• Strong Return on Hard NAV1 of £117.9m, or 9%, (HY20: £14.2m; FY20: £189.5m)
• Hard NAV2 of £1,439.3m or 135.4 pence per share (HY20: £1,156.4m or 108.8pps; FY20: £1,331.5m or 125.3pps)
• Cash realisations of £111.4m (HY20: £113.7m; FY20: £191.0m)
• Sustained investment into portfolio: £69.5m into 41 companies (HY20 £36.9m; FY20: £67.5m)
• Interim dividend of 0.48p per share and £20m allocated to buying back the Group’s shares

Initial upswing in NAV and sp following results this week (hence why July last opportunity to get in at 110 or below). Shareprice at 150-180+ following nanopore IPO.

Respect your opinion. We shall see won’t we. I will acknowledge if you are right. Expect you to do the same if I am :)

Very quiet on this board nowadays. I know I'm just a random stranger to you, and don't expect anyone to trust my opinion, however, just wanted to put it out there that I predict (for reasons set out in previous posts) that July will be the very last opportunity to buy IP group at these levels. In fact, I think the stock is deliberately being driven down so institutions can load up prior to the big nanopore IPO news. Good luck to all

Great time to buy IMO, oversold now due to market woes (covid, economic recovery) that could actually help ensure max. valuation of Oxford nanopore at upcoming IPO. ONT have many many strings to their bow, however covid surveillance (a huge and global market that will last years, perhaps forever) is and will be a catalyst for their revenue growth and expanded customer base. And ONT, of course just one of >100 companies we gain exposure to through IP group. I bought more yesterday at 111p.

Incredible news from Intellia (in vivo CRISPR/Cas9 gene editing breakthrough). Will boost all related genomics stocks, including sequencing (i.e. nanopore valuation) as key part of the infrastructure for this sector

Anyone who thinks NAV/shareprice won't be >£1.6bn/150pps once Oxford Nanopore floats later this year has not done their research. Oxford nanopore listing at £4bn is conservative. Important to understand the genomics sector and the market opportunity for long read sequencing. Only two real players (ONT and Pacific Biosciences) for what will quickly become a huge market, already catalysed by SARS-Cov2 genomic surveillance, which is nothing compared to clinical diagnostics/population-scale sequencing ($20bn addressable market in <5yrs). Very exciting times and days like today, great for adding to holding

Beardozer, unfortunately (for you) you have miscalculated SUPP oxford nanopore holding. Yes Oxford nanopore is 21% of SUPP portfolio, but they only hold <4% of ONT, valued currently at £68.7m (note- SUPP still using ONT valuation of £1.9bn to calculate their NAV).

I don't have level 2, but I've been monitoring trades over last few days/weeks, since some weird activity - some low volume trades going through well outside lower daily range. I can only assume it's MMs trying to trigger stop losses to fill large orders. Take this morning for example - 4 shares sold at 111.4p!! Anyone with level 2 care to share their insight?

Not sure why no RNS yet, but this is amazing news. WaveOptics being acquired for $500m+. IP group stake is 17.1% !!
https://www.ft.com/content/6416472c-fcad-4b1d-82c0-aa8fa9e8947c

I think recent drop is linked to Nasdaq drop due to inflation fears and shorting of growth stocks. Nasdaq tech stocks turning around now, so expect IP group shareprice to do the same over coming week or so. I enjoyed the opportunity to add more below 120pps. Much upside still from here IMO

Crescendo is other potential acquisition target and will be for far more than Kurr or Inviata :)

Nanopore listing at £4bn (conservative in my view) = IP Group hard NAV £1.59bn = IP group shareprice circa 150pps
Nanopore listing at £7bn = IP Group hard NAV £2.04bn = IP group shareprice circa 192pps

Destiny is at one of those moments for investors where SP will drift sideways due to no news, but if/when BIG news comes (partnership or acquisition) there will be no way back in for investors who haven't held a position....

Hi Jurado, I think the PsiOxus news re. extended development partnership with BMS is fantastic news. Reminds us that IP group portfolio is not a 'one trick pony' (nanopore), acknowledging that nanopore is an incredible company and current valuation (circa £2bn) is the tip of the iceberg for where it and genomics sector is heading.
I'm very exicted about IP group's substantial holdings in clinical stage oncology (cancer) companies, including PsiOxus, Inviata, Kuur, Crescendo. Recent re-rate is just the beginning IMHO.

Today, the penny has dropped!

The news we have all been waiting for!! I've been invested in and following genomics-related companies for >15 years. What a fantastic company Oxford Nanopore is. Great for the UK that they are listing in London and investing heavily in UK capabilities.
What an opportunity to be part of this story, prior to IPO, via IP group!!! I'm still buying every month and will continue to do so for the foreseeable, whilst saving some pennies to be part of Oxford IPO.

Recommend to read full announcement at Oxford Nanopore website/NEWS

To new would-be-investors:
-Destiny is at inflection point, with positive XF-73 Ph2b results (in prevention of postsurgical staph, including MRSA infections - a multi billion $ global market) announced today!
- New preclinical development partnerships to expand future addressable market for XF compounds - a preventative indication for severe wounds would be a HUGE market, even bigger than the massive market above
- Another Phase 3 ready product with potential >$1bn market!
- A likely partnership (or aquisition) with complementary big pharma co. on the cards
- A 2021 big pharma acquisition would be for several hundred million £
- If licensing deal with big pharma, a 3-5 year market cap of £1bn (>£17 shareprice) is not unrealistic here

To new would-be-investors here:
-Destiny is at inflection point, with XF-73 Ph2b results (in prevention of postsurgical staph, including MRSA infections - a multi billion $ global market) due in a matter of days
- New preclinical development partnerships to expand future addressable market for XF compounds - a preventative infection for severe wounds would be a HUGE market, even bigger than the massive market above (which is on cusp of proof-of-efficacy - aka to show the treatment works)
- Other exciting products in increasingly diverse drug pipeline (see website)
- A likely partnership (or aquisition) with complementary big pharma co. on the cards
- A 2021 big pharma acquisition would be for several hundred million £
- 3-5 year market cap of >£1bn (£17 shareprice) could be conservative here

Strong NAV growth, solid financials, a dividend and Oxford nanopore IPO on near-term horizon, which could easily double NAV here. What more could we ask for?